Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

1018 ISS

Drug Profile

1018 ISS

Alternative Names: First generation 1018 ISS - Dynavax; ISS 1018; ISS DNA; ISS1; ISS2

Latest Information Update: 16 Oct 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Developer Dana-Farber Cancer Institute; Dynavax Technologies
  • Class DNA; Oligonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Allergic asthma
  • Discontinued Colorectal cancer; Human papillomavirus infections; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Apr 2008 Discontinued - Preclinical for Human papillomavirus infections in USA (unspecified route)
  • 08 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the adverse events section
  • 30 Nov 2006 Phase-I clinical trials in Colorectal cancer (combination therapy, second-line therapy or greater) in USA (SC) (NCT00403052)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top